NO313863B1 - Addukt og absorberende bandasje omfattende adduktet, samt anvendelse av adduktet for fremstilling av et medikament fortopisk behandling av hudsÕr - Google Patents
Addukt og absorberende bandasje omfattende adduktet, samt anvendelse av adduktet for fremstilling av et medikament fortopisk behandling av hudsÕr Download PDFInfo
- Publication number
- NO313863B1 NO313863B1 NO19971926A NO971926A NO313863B1 NO 313863 B1 NO313863 B1 NO 313863B1 NO 19971926 A NO19971926 A NO 19971926A NO 971926 A NO971926 A NO 971926A NO 313863 B1 NO313863 B1 NO 313863B1
- Authority
- NO
- Norway
- Prior art keywords
- adduct
- wound
- absorbent bandage
- bandage according
- water
- Prior art date
Links
- 239000002250 absorbent Substances 0.000 title claims description 20
- 230000002745 absorbent Effects 0.000 title claims description 20
- 238000004519 manufacturing process Methods 0.000 title claims description 17
- 230000000699 topical effect Effects 0.000 title claims description 14
- 239000003814 drug Substances 0.000 title claims description 5
- 206010040943 Skin Ulcer Diseases 0.000 title 1
- 231100000019 skin ulcer Toxicity 0.000 title 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 179
- 208000027418 Wounds and injury Diseases 0.000 claims description 65
- 229920000642 polymer Polymers 0.000 claims description 30
- 150000004676 glycans Chemical class 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 14
- 229920001282 polysaccharide Polymers 0.000 claims description 14
- 239000005017 polysaccharide Substances 0.000 claims description 14
- 239000011159 matrix material Substances 0.000 claims description 13
- 239000001913 cellulose Substances 0.000 claims description 10
- 229920002678 cellulose Polymers 0.000 claims description 10
- 238000004132 cross linking Methods 0.000 claims description 8
- 229920002873 Polyethylenimine Polymers 0.000 claims description 7
- 229920002367 Polyisobutene Polymers 0.000 claims description 6
- 230000035876 healing Effects 0.000 claims description 6
- 239000011859 microparticle Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 229920002307 Dextran Polymers 0.000 claims description 5
- 230000002209 hydrophobic effect Effects 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 230000036760 body temperature Effects 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 239000002998 adhesive polymer Substances 0.000 claims description 3
- 229920000249 biocompatible polymer Polymers 0.000 claims description 3
- 125000005587 carbonate group Chemical group 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 230000009477 glass transition Effects 0.000 claims description 3
- 229920003176 water-insoluble polymer Polymers 0.000 claims description 3
- 229920000742 Cotton Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 206010072170 Skin wound Diseases 0.000 claims description 2
- 229920005549 butyl rubber Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 229920003048 styrene butadiene rubber Polymers 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 description 64
- 241000700159 Rattus Species 0.000 description 24
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 23
- 239000000047 product Substances 0.000 description 21
- 229910002651 NO3 Inorganic materials 0.000 description 20
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical class CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 20
- 239000007789 gas Substances 0.000 description 15
- 230000002485 urinary effect Effects 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 230000029663 wound healing Effects 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 210000002700 urine Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 230000035488 systolic blood pressure Effects 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 6
- 239000001307 helium Substances 0.000 description 6
- 229910052734 helium Inorganic materials 0.000 description 6
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 6
- 239000004005 microsphere Substances 0.000 description 6
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 4
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- -1 cyanogen halide Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940028978 brevital Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- KDXZREBVGAGZHS-UHFFFAOYSA-M methohexital sodium Chemical compound [Na+].CCC#CC(C)C1(CC=C)C(=O)N=C([O-])N(C)C1=O KDXZREBVGAGZHS-UHFFFAOYSA-M 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229920000768 polyamine Polymers 0.000 description 3
- 150000004804 polysaccharides Polymers 0.000 description 3
- 235000010333 potassium nitrate Nutrition 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 230000037314 wound repair Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 208000034657 Convalescence Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- ZIIQCSMRQKCOCT-YFKPBYRVSA-N S-nitroso-N-acetyl-D-penicillamine Chemical compound CC(=O)N[C@@H](C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-YFKPBYRVSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000000416 hydrocolloid Substances 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002840 nitric oxide donor Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 239000004533 oil dispersion Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229920002379 silicone rubber Polymers 0.000 description 2
- 239000004945 silicone rubber Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 2
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 1
- 241000931526 Acer campestre Species 0.000 description 1
- 101001053395 Arabidopsis thaliana Acid beta-fructofuranosidase 4, vacuolar Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 150000004007 S-nitroso compounds Chemical class 0.000 description 1
- 108010093594 S-nitrosoalbumin Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 229910021551 Vanadium(III) chloride Inorganic materials 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 206010068796 Wound contamination Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229920006125 amorphous polymer Polymers 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical group BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
- 229960004027 molsidomine Drugs 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960002460 nitroprusside Drugs 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000005554 pickling Methods 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- HQYCOEXWFMFWLR-UHFFFAOYSA-K vanadium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[V+3] HQYCOEXWFMFWLR-UHFFFAOYSA-K 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000011706 wistar kyoto rat Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/114—Nitric oxide, i.e. NO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/330,596 US5519020A (en) | 1994-10-28 | 1994-10-28 | Polymeric wound healing accelerators |
PCT/US1995/014071 WO1996013164A1 (fr) | 1994-10-28 | 1995-10-30 | Accelerateurs de cicatrisation a base de polymeres |
Publications (3)
Publication Number | Publication Date |
---|---|
NO971926D0 NO971926D0 (no) | 1997-04-25 |
NO971926L NO971926L (no) | 1997-06-10 |
NO313863B1 true NO313863B1 (no) | 2002-12-16 |
Family
ID=23290462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19971926A NO313863B1 (no) | 1994-10-28 | 1997-04-25 | Addukt og absorberende bandasje omfattende adduktet, samt anvendelse av adduktet for fremstilling av et medikament fortopisk behandling av hudsÕr |
Country Status (11)
Country | Link |
---|---|
US (1) | US5519020A (fr) |
EP (1) | EP0788308B1 (fr) |
JP (1) | JP4072736B2 (fr) |
KR (1) | KR100408772B1 (fr) |
AU (1) | AU688627B2 (fr) |
CA (1) | CA2203901C (fr) |
DE (1) | DE69533166T2 (fr) |
DK (1) | DK0788308T3 (fr) |
ES (1) | ES2224138T3 (fr) |
NO (1) | NO313863B1 (fr) |
WO (1) | WO1996013164A1 (fr) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5691423A (en) * | 1992-08-24 | 1997-11-25 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-bound nitric oxide-nucleophile adducts |
US5632981A (en) * | 1992-08-24 | 1997-05-27 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
US6190704B1 (en) * | 1994-09-23 | 2001-02-20 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Regulation of wound healing by nitric oxide |
US5817145A (en) * | 1994-11-21 | 1998-10-06 | Augustine Medical, Inc. | Wound treatment device |
WO1997033989A1 (fr) * | 1996-03-15 | 1997-09-18 | The General Hospital Corporation | ANIMAUX TRANSGENIQUES PRESENTANT UN GENE eNOS A ACTIVITE PERTURBEE ET LEUR UTILISATION |
US6232434B1 (en) * | 1996-08-02 | 2001-05-15 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
US5861149A (en) * | 1997-06-04 | 1999-01-19 | Polyheal Ltd. | Methods for wound treatment |
US6221425B1 (en) | 1998-01-30 | 2001-04-24 | Advanced Cardiovascular Systems, Inc. | Lubricious hydrophilic coating for an intracorporeal medical device |
US6103275A (en) * | 1998-06-10 | 2000-08-15 | Nitric Oxide Solutions | Systems and methods for topical treatment with nitric oxide |
US20040043068A1 (en) * | 1998-09-29 | 2004-03-04 | Eugene Tedeschi | Uses for medical devices having a lubricious, nitric oxide-releasing coating |
CA2254645A1 (fr) * | 1998-11-23 | 2000-05-23 | Pulmonox Medical Corporation | Methode et appareil pour traiter les infections respiratoires par l'inhalation d'oxyde nitrique |
US20070086954A1 (en) * | 1998-11-23 | 2007-04-19 | Miller Christopher C | Method and apparatus for treatment of respiratory infections by nitric oxide inhalation |
US6261594B1 (en) | 1998-11-25 | 2001-07-17 | The University Of Akron | Chitosan-based nitric oxide donor compositions |
DE19945484A1 (de) * | 1999-09-22 | 2001-04-05 | Kolb Bachofen Victoria | NO-freisetzende topisch applizierbare Zusammensetzung |
US6737447B1 (en) | 1999-10-08 | 2004-05-18 | The University Of Akron | Nitric oxide-modified linear poly(ethylenimine) fibers and uses thereof |
US7516742B2 (en) * | 1999-11-24 | 2009-04-14 | Cardinal Health 207, Inc. | Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing |
US6270779B1 (en) * | 2000-05-10 | 2001-08-07 | United States Of America | Nitric oxide-releasing metallic medical devices |
BRPI0113085B1 (pt) * | 2000-08-11 | 2017-09-19 | R. Whitlock David | Preparation to be applied to a surface of an individual understanding ammonia oxidizing bacteria that metabolize transparation, and clothing article |
WO2002043731A2 (fr) * | 2000-11-30 | 2002-06-06 | University Of Florida | Traitements de troubles neurogenetiques, de troubles du controle des impulsions, et cicatrisation des lesions |
US6780849B2 (en) * | 2000-12-21 | 2004-08-24 | Scimed Life Systems, Inc. | Lipid-based nitric oxide donors |
US7122018B2 (en) * | 2000-12-26 | 2006-10-17 | Sensormedics Corporation | Device and method for treatment of wounds with nitric oxide |
US6432077B1 (en) * | 2000-12-26 | 2002-08-13 | Sensormedics Corporation | Device and method for treatment of surface infections with nitric oxide |
WO2003026717A1 (fr) * | 2001-09-26 | 2003-04-03 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Dispositifs medicaux revetus a liberation d'oxyde nitrique et leur procede de preparation |
US6703046B2 (en) | 2001-10-04 | 2004-03-09 | Medtronic Ave Inc. | Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use |
AU2003222569A1 (en) * | 2002-01-11 | 2003-07-24 | Whitlock, David R. | Compositions including ammonia oxidizing bacteria and methods of using same |
US7531133B2 (en) * | 2002-09-10 | 2009-05-12 | Pulmonox Technologies Corporation | Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma |
ES2713058T3 (es) * | 2003-04-23 | 2019-05-17 | Univ Akron | Materiales reactivos secuestrados |
WO2004103416A2 (fr) * | 2003-05-20 | 2004-12-02 | Avery Dennison Corporation | Pate adhesive absorbant les liquides |
WO2004103415A2 (fr) * | 2003-05-20 | 2004-12-02 | Avery Dennison Corporation | Systeme a pansements multiples pour la gestion de lesions cutanees |
WO2004103432A2 (fr) * | 2003-05-20 | 2004-12-02 | Avery Dennison Corporation | Masques faciaux pour traiter des plaies cutanees |
WO2005011575A2 (fr) * | 2003-07-25 | 2005-02-10 | The University Of Akron | Stabilisation et declenchement ionique de la liberation d'oxyde nitrique |
WO2005070008A2 (fr) | 2004-01-22 | 2005-08-04 | The University Of Akron | Revetement en nanofibres de promedicament donneur de non polymerique pour des dispositifs medicaux et therapie associee |
US7569559B2 (en) * | 2004-02-09 | 2009-08-04 | Noxilizer, Inc. | Nitric oxide-releasing molecules |
JP4738352B2 (ja) * | 2004-02-09 | 2011-08-03 | アミュレット ファーマシューティカルズ インコーポレイティッド | 一酸化窒素放出ポリマー |
EP1750782A1 (fr) * | 2004-04-29 | 2007-02-14 | Cube Medical A/S | Ballonnet a utiliser dans l'angioplastie, comportant une couche exterieure de nanofibres |
US8518457B2 (en) * | 2004-05-11 | 2013-08-27 | Pulmonox Technologies Corporation | Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant |
MXPA06013111A (es) * | 2004-05-11 | 2007-05-23 | Sensormedics Corp | Dosificacion intermitente de gas de oxido nitrico. |
US20070154570A1 (en) * | 2004-09-29 | 2007-07-05 | Miller Christopher C | Use of nitric oxide in the treatment and disinfection of biofilms |
WO2006083927A2 (fr) | 2005-01-31 | 2006-08-10 | Coram Bioscience, Inc. | Agent antimicrobien |
ATE407708T1 (de) * | 2005-02-11 | 2008-09-15 | Nolabs Ab | Vorrichtung und verfahren zur behandlung von dermatomykosen und insbesondere onychomykosen |
DK1846058T3 (da) * | 2005-02-11 | 2009-11-23 | Nolabs Ab | Indretning, fremgangsmåde og anvendelse til behandling af neuropati med nitrogenoxid |
EP1846009A2 (fr) * | 2005-02-11 | 2007-10-24 | NOLabs AB | Dispositif d'application de medicaments ameliore, procede de fabrication de celui-ci et procede de traitement |
EP1690558A1 (fr) * | 2005-02-11 | 2006-08-16 | NOLabs AB | Dispositif de traitment de troubles d'origine diabetique |
EP1700611A1 (fr) * | 2005-02-11 | 2006-09-13 | NOLabs AB | Dispositif de traitement de troubles dans la cavité buccale et son procédé de fabrication |
EP1757278A1 (fr) * | 2005-08-23 | 2007-02-28 | NOLabs AB | Dispositif, système ou méthode contenant un liquide microencapsulé pour la libération d'oxyde nitrique à partir d'un polymère |
US8119840B2 (en) * | 2005-03-04 | 2012-02-21 | The University Of Akron | Ethambutol based nitric oxide donors |
DE602006006432D1 (de) | 2005-03-24 | 2009-06-04 | Nolabs Ab | Kosmetische behandlung mit stickoxid, vorrichtung zur durchführung dieser behandlung und herstellungsverfahren dafür |
EP1704879A1 (fr) * | 2005-03-24 | 2006-09-27 | NOLabs AB | Appareil médical intravasculaire, interstitiel ou d'accès à l'intérieur d'un organe comprenant un polymère à élution de monoxide d'azote |
EP1704877A1 (fr) * | 2005-03-24 | 2006-09-27 | NOLabs AB | Dispositif de traitement des plaies comprenant un polymère à élution de monoxyde d'azote |
WO2006100155A1 (fr) * | 2005-03-24 | 2006-09-28 | Nolabs Ab | Dispositif pour le soin des plaies, et procede de fabrication associe, impliquant l'utilisation de monoxyde d'azote |
US20090039565A1 (en) * | 2005-04-21 | 2009-02-12 | The University Of Akron | Process for producing fibers and their uses |
CA2912259C (fr) | 2005-05-27 | 2020-04-28 | Mark H. Schoenfisch | Particules liberant de l'oxyde nitrique pour therapie a base d'oxyde nitrique et applications biomedicales |
US20070116785A1 (en) * | 2005-11-18 | 2007-05-24 | Miller Christopher C | Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant |
US20070196327A1 (en) * | 2005-12-06 | 2007-08-23 | Amulet Pharmaceuticals, Inc. | Nitric oxide releasing polymers |
US20070276309A1 (en) * | 2006-05-12 | 2007-11-29 | Kci Licensing, Inc. | Systems and methods for wound area management |
US20070276195A1 (en) * | 2006-05-12 | 2007-11-29 | Kci Licensing, Inc. | Systems and methods for wound area management |
US20080033048A1 (en) * | 2006-05-19 | 2008-02-07 | Smith Daniel J | Piggyback bifunctional vasodilators |
US8079998B2 (en) * | 2006-10-20 | 2011-12-20 | Pulmonox Technologies Corporation | Methods and devices for the delivery of therapeutic gases including nitric oxide |
US20080193385A1 (en) * | 2007-02-08 | 2008-08-14 | Todd Maibach | Compositions and methods for treating neuropathy |
US20080193566A1 (en) * | 2007-02-09 | 2008-08-14 | Miller Christopher C | Use of high dose concentrations of gaseous nitric oxide |
JP5172940B2 (ja) * | 2007-03-27 | 2013-03-27 | ノーラブズ エービー | 一酸化窒素送達のための局所皮膚送達装置 |
WO2009093169A1 (fr) * | 2008-01-22 | 2009-07-30 | Koninklijke Philips Electronics N.V. | Dispositif d'administration topique d'oxyde nitrique sur une surface cutanée |
US8425837B2 (en) | 2009-02-23 | 2013-04-23 | Noxilizer, Inc. | Device and method for gas sterilization |
US9526738B2 (en) | 2009-08-21 | 2016-12-27 | Novan, Inc. | Topical gels and methods of using the same |
US9919072B2 (en) | 2009-08-21 | 2018-03-20 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
US20110139163A1 (en) * | 2009-12-15 | 2011-06-16 | Hillila David J | Vibration apparatus for stimulating paranasal sinuses |
US8499764B2 (en) | 2010-05-26 | 2013-08-06 | The Invention Science Fund I, Llc | Portable apparatus for establishing an isolation field |
US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
WO2012118819A2 (fr) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Particules de silice modifiées par des groupements s-nitrosothiols libérant de l'oxyde nitrique et procédés de fabrication associés |
EP2729131B1 (fr) | 2011-07-05 | 2020-04-15 | Novan, Inc. | Compositions topiques |
US9855211B2 (en) | 2013-02-28 | 2018-01-02 | Novan, Inc. | Topical compositions and methods of using the same |
JP6513667B2 (ja) | 2013-08-08 | 2019-05-15 | ノヴァン,インコーポレイテッド | 局所用組成物およびそれを使用する方法 |
EP4219679A3 (fr) | 2014-04-15 | 2023-08-09 | Aobiome LLC | Souche d23 de nitrosomonas eutropha oxydant l'ammoniac |
US11225640B2 (en) | 2014-04-15 | 2022-01-18 | Aobiome Llc | Ammonia oxidizing bacteria for treatment of psoriasis |
EP3177262A4 (fr) | 2014-08-08 | 2018-04-18 | Novan Inc. | Émulsions topiques |
US10912743B2 (en) | 2016-03-02 | 2021-02-09 | Novan, Inc. | Compositions for treating inflammation and methods of treating the same |
BR112018070578A2 (pt) | 2016-04-13 | 2019-02-12 | Novan, Inc. | composições, sistemas, kits, e métodos para tratar uma infecção |
EP3246050A1 (fr) * | 2016-05-17 | 2017-11-22 | BSN medical GmbH | Timbre transdermique ou pansement |
CN110446521B (zh) | 2017-01-21 | 2022-05-06 | 生物克瑞德公司 | 配置用于一氧化氮的控制释放的医疗产品和方法 |
WO2018190613A1 (fr) * | 2017-04-10 | 2018-10-18 | 부산대학교 산학협력단 | Composition de poudre hydrogélifiée pour la cicatrisation de plaies et son procédé de production |
KR102668789B1 (ko) | 2018-11-23 | 2024-05-24 | (주)메디코스바이오텍 | 창상치료용 약학조성물 |
US20210338461A1 (en) * | 2020-04-30 | 2021-11-04 | Becton, Dickinson And Company | Nitric oxide infused surgical tissue repair technologies |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4535154A (en) * | 1981-07-13 | 1985-08-13 | United States Of America | Reductive destruction of nitrosamines, hydrazines, nitramines, azo- and azoxy-compounds |
US4954526A (en) * | 1989-02-28 | 1990-09-04 | The United States Of America As Represented By The Department Of Health And Human Services | Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents |
US5216025A (en) * | 1989-09-13 | 1993-06-01 | Board Of Regents, The University Of Texas System | Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients |
US5059712A (en) * | 1989-09-13 | 1991-10-22 | Cornell Research Foundation, Inc. | Isolating aminoarginine and use to block nitric oxide formation in body |
US5028627A (en) * | 1989-09-13 | 1991-07-02 | Cornell Research Foundation, Inc. | Method of using arginine derivatives to inhibit systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor |
US5158883A (en) * | 1989-09-13 | 1992-10-27 | Cornell Research Foundation, Inc. | Method of using aminoarginine to block nitric oxide formation in vitro |
US5039705A (en) * | 1989-09-15 | 1991-08-13 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof |
US5208233A (en) * | 1989-09-15 | 1993-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof |
US5212204A (en) * | 1989-10-18 | 1993-05-18 | The United States Of America As Represented By The Department Of Health And Human Services | Antihypertensive compositions and use thereof |
US5196195A (en) * | 1990-03-27 | 1993-03-23 | Cornell Research Foundation, Inc. | Use of arginase to control nitric oxide formation |
US5155137A (en) * | 1990-09-20 | 1992-10-13 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Complexes of nitric oxide with polyamines |
US5132453A (en) * | 1991-03-22 | 1992-07-21 | Cornell Research Foundation, Inc. | N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body |
US5198428A (en) * | 1991-04-05 | 1993-03-30 | Board Of Regents, The Univ. Of Texas System | Macrophage cytotoxin compositions and methods of preparation |
US5185376A (en) * | 1991-09-24 | 1993-02-09 | The United States Of America As Represented By The Department Of Health And Human Services | Therapeutic inhibition of platelet aggregation by nucleophile-nitric oxide complexes and derivatives thereof |
US5549908A (en) * | 1993-05-20 | 1996-08-27 | The University Of Akron | Hydrolytically labile microspheres of polysaccharide crosslinked with cyanogen halide and their application in wound dressings |
US6190704B1 (en) * | 1994-09-23 | 2001-02-20 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Regulation of wound healing by nitric oxide |
-
1994
- 1994-10-28 US US08/330,596 patent/US5519020A/en not_active Expired - Lifetime
-
1995
- 1995-10-30 KR KR1019970702805A patent/KR100408772B1/ko active IP Right Grant
- 1995-10-30 JP JP51481996A patent/JP4072736B2/ja not_active Expired - Fee Related
- 1995-10-30 AU AU39715/95A patent/AU688627B2/en not_active Expired
- 1995-10-30 CA CA002203901A patent/CA2203901C/fr not_active Expired - Lifetime
- 1995-10-30 ES ES95937679T patent/ES2224138T3/es not_active Expired - Lifetime
- 1995-10-30 DK DK95937679T patent/DK0788308T3/da active
- 1995-10-30 EP EP95937679A patent/EP0788308B1/fr not_active Expired - Lifetime
- 1995-10-30 WO PCT/US1995/014071 patent/WO1996013164A1/fr active IP Right Grant
- 1995-10-30 DE DE69533166T patent/DE69533166T2/de not_active Expired - Lifetime
-
1997
- 1997-04-25 NO NO19971926A patent/NO313863B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
MX9703084A (es) | 1997-07-31 |
JP4072736B2 (ja) | 2008-04-09 |
WO1996013164A1 (fr) | 1996-05-09 |
AU688627B2 (en) | 1998-03-12 |
DK0788308T3 (da) | 2004-11-01 |
EP0788308B1 (fr) | 2004-06-16 |
KR100408772B1 (ko) | 2004-03-31 |
NO971926L (no) | 1997-06-10 |
JPH10508305A (ja) | 1998-08-18 |
EP0788308A4 (fr) | 2000-05-31 |
DE69533166T2 (de) | 2005-07-14 |
US5519020A (en) | 1996-05-21 |
CA2203901C (fr) | 2008-01-08 |
AU3971595A (en) | 1996-05-23 |
EP0788308A1 (fr) | 1997-08-13 |
NO971926D0 (no) | 1997-04-25 |
ES2224138T3 (es) | 2005-03-01 |
DE69533166D1 (de) | 2004-07-22 |
CA2203901A1 (fr) | 1996-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO313863B1 (no) | Addukt og absorberende bandasje omfattende adduktet, samt anvendelse av adduktet for fremstilling av et medikament fortopisk behandling av hudsÕr | |
Singh et al. | Sterculia crosslinked PVA and PVA-poly (AAm) hydrogel wound dressings for slow drug delivery: mechanical, mucoadhesive, biocompatible and permeability properties | |
CN110446521B (zh) | 配置用于一氧化氮的控制释放的医疗产品和方法 | |
US9655840B2 (en) | Wound care products | |
US9662414B2 (en) | Dressing system | |
Brisbois et al. | Improved hemocompatibility of multilumen catheters via nitric oxide (NO) release from S-nitroso-N-acetylpenicillamine (SNAP) composite filled lumen | |
US20120184898A1 (en) | Gas based wound and tissue therapeutics | |
EP3380090A1 (fr) | Système de pansement | |
EP1272231A1 (fr) | Compositions et methodes visant a favoriser la cicatrisation | |
WO1994024181A1 (fr) | Revetements resistants aux incrustations et aux bacteries, destines a des applications medicales | |
KR20070080823A (ko) | 활성약물 함유 상처 치료용 하이드로겔 제제 | |
WO2004002460A1 (fr) | Pansement impregne | |
Thomas | Hydrocolloids | |
JP2008536978A (ja) | ピロリドン側基を含む生分解性ポリホスファゼン | |
CN112972757A (zh) | 一种全氟萘烷水凝胶促愈合敷料及其制备方法和用途 | |
WO1999026984A1 (fr) | Modification de l'heparine de faible masse moleculaire et remede contre l'ulcere de la peau | |
EP1633408B1 (fr) | Dispositif de soin des plaies | |
Thomas | Vapour-permeable film dressings | |
MXPA97003084A (en) | Polymeric accelerators for the curing of heri | |
CN114796100A (zh) | 一种吡罗昔康凝胶贴膏剂及其制备方法 | |
WO1997029777A1 (fr) | Systeme d'administration de medicament utilisant une galactoxyloglucane | |
KR101106348B1 (ko) | 생적합성 중합체 | |
CN115737903B (zh) | 多重响应性智能抗菌mof复合水凝胶及其制备方法和用途 | |
KR20220009041A (ko) | 당뇨병 환자를 위한 상처 치유 억제용 패치 | |
CN114224914A (zh) | 一种抗微生物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |